Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC competition clears advisory panel

This article was originally published in The Tan Sheet

Executive Summary

FDA's Advisory Committee for Reproductive Health Drugs June 17 votes unanimously in favor of approving Watson Pharmaceuticals' emergency contraceptive ulipristal acetate, marketed in Europe as ellaOne by HRA Pharma. Collins Stewart analyst Louise Chen said in a same-day note the panel's decision bodes well for FDA approval and a likely early 2011 launch for UPA, which Chen expects to compete with Teva's Plan B One-Step (levonorgestrel). Although UPA would be available Rx-only upon approval, Watson CEO Paul Bisaro has stated an interest in switching the next-generation EC to nonprescription status (1"The Tan Sheet" March 15, 2010, In Brief)
Advertisement

Related Content

Watson plans OTC switch for EC

Topics

Advertisement
UsernamePublicRestriction

Register

PS104222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel